Adamantinomatous craniopharyngioma associated with a compromised blood-brain barrier: patient series.

ABSTRACT:

Background

Adamantinomatous craniopharyngioma (ACP) is a highly morbid adult and pediatric brain tumor derived from epithelial remnants of the craniopharyngeal canal (Rathke's pouch), which gives rise to the anterior pituitary gland. Standard therapy includes maximal safe resection with or without radiation therapy. Systemic antitumor therapy remains elusive. Immune-related paracrine signaling involving the interleukin-6 receptor (IL-6R) may contribute to ACP pathogenesis. Tocilizumab, a recombinant humanized monoclonal antibody against IL-6R, is approved by the US Food and Drug Administration but does not cross an intact blood-brain barrier.

Observations

In a phase 0 trial design, a single dose of tocilizumab was delivered intravenously before clinically indicated surgical

SUBMITTER: Prince EW 

PROVIDER: S-EPMC9245763 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature